111, Inc. — Form SCHEDULE 13D
Filed September 17, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 73/100
What the filing says
On September 16, 2026, a consortium led by co-founders Dr. Gang Yu and Mr. Junling Liu, plus sponsor Huadeng Tech BioArray Ventures Ltd, proposed acquiring all Class A shares of 111, Inc. not owned by them at $0.226 per share ($4.52 per ADS)—a 29.5% premium to the prior trading close and 20% above the 60-day average. The co-founders currently own ~41.6% of capitalization and 91.3% of voting power; Huadeng will contribute ~$20.7M cash while co-founders roll over ~$16.6M in existing shares. The transaction requires special committee approval, has no financing condition, and is governed by a binding consortium agreement dated September 16, 2026.
Why this rating
Going-private at $0.226/share significantly restructures capital, affecting all public shareholders. Relative to ~$315M total assets, ~$37.4M equity raise is ~12% of company size—material but execution-dependent. Neutral impact pending special committee review and deal closure.
Price action (we called it neutral)
before filing · preread $3.68 ▲ 5.26% | at our read · unknown $3.50 | +10 min · unknown $3.55 ▲ 1.46% | +30 min · unknown $3.41 ▼ 2.54% | +1 hr · unknown $3.41 ▼ 2.54% | +4 hrs · unknown $3.44 ▼ 1.69% |
The stock had already moved -5.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.